品牌现货直购
供应商:我要出现这里




查看所有供应商和价格请点击:

55-98-1生产厂家

55-98-1价格

55-98-1

55-98-1结构式
55-98-1结构式

化源商城直购

中文名 白消安
英文名 busulfan
中文别名 二甲磺酸-1,4-丁二醇
二甲磺酸丁酯
1,4-双甲基磺氧基丁烷
不育磺
1,4-丁二醇二甲烷磺酸盐
英文别名 4-methylsulfonyloxybutyl methanesulfonate
Myelosan
Misulban
1,4-Butanediyl dimethanesulfonate
Mitosan
Tetramethylenester kyseliny methansulfonove [Czech]
butane-1,4-diyl di(methanesulfonate)
Butan-1,4-diyldimethansulfonat
1,4-Butanediol Dimesylate
Busulfan
4-((Methylsulfonyl)oxy)butyl methanesulfonate
tetramethylene di(methanesulfonate)
Leucosulfan
Myleran
UNII-G1LN9045DK
2041 C.B.
Busulfex
(1,4-Bis(methanesulfonyloxy)butane)
Mitostan
1,4-Di(methanesulfonyloxy)butane
busulphan
Myeloleukon
1,4-Butanediol, dimethanesulfonate
Mylecytan
Butane-1,4-diyl dimethanesulfonate
Methanesulfonic Acid Tetramethylene Ester
Mielucin
MFCD00007562
EINECS 200-250-2
描述 Busulfan 是一种有效的烷化剂 (alkylator),具有化疗作用。
相关类别
靶点

DNA Alkylator[1]

体外研究 白消安是一种有效的烷化剂,可用作化学治疗剂。 Busulfan(120μM)通过Erk和p38 MAPK途径导致WI38细胞过早衰老,降低GSH并增加ROS产生,但NADPH氧化酶可抑制产生[1]。
体内研究 白消安(40mg/kg,ip)增加细胞凋亡并降低小鼠的睾丸重量。与对照相比,Busulfan处理小鼠的睾丸表现出更高水平的pRB表达,抑制Rb磷酸化和PCNA表达[2]。 Busulfan(2.5,5.0 mg/kg,ip)在大鼠中以剂量依赖性方式导致早期出现持续性esturs。白消安(5.0 mg/kg)也会增加子宫腺癌的发病率和子宫肿瘤病变的多样性。此外,Busulfan降低大鼠血清17β-雌二醇(E2),孕酮和抑制素水平,并且仅在5.0 mg/kg时提高E2 /孕酮比例[3]。
细胞实验 将WI38细胞以60,000个细胞/孔接种于24孔板的孔中并培养过夜。用Busulfan处理它们24小时,然后除去药物并将细胞在新鲜培养基中培养最多11天。未处理的细胞用作对照。每3天对细胞进行胰蛋白酶消化,计数并在1:5和1:2稀释的新鲜培养基中进行传代培养,分别用于对照未处理和经Busulfan处理的细胞[1]。
动物实验 小鼠[2]使用120只年龄为8至12周(30-40g)的ICR雄性小鼠。 8周龄ICR雄性小鼠接受单次腹膜内注射用芝麻油稀释的Busulfan(40mg / kg)。将小鼠置于22±1℃的线笼中,12小时光暗循环,70%湿度,随意喂食[2]。
参考文献

[1]. Probin V, et al. Busulfan-induced senescence is dependent on ROS production upstream of the MAPK pathway. Free Radic Biol Med. 2007 Jun 15;42(12):1858-65. Epub 2007 Mar 31.

[2]. Choi YJ, et al. Murine male germ cell apoptosis induced by busulfan treatment correlates with loss of c-kit-expression in a Fas/FasL- and p53-independent manner. FEBS Lett. 2004 Sep 24;575(1-3):41-51.

[3]. Yoshida M, et al. Reduction of primordial follicles caused by maternal treatment with busulfan promotes endometrial adenocarcinoma development in donryu rats. J Reprod Dev. 2005 Dec;51(6):707-14. Epub 2005 Sep 22.

密度 1.4±0.1 g/cm3
沸点 464.0±28.0 °C at 760 mmHg
熔点 114-117 °C(lit.)
分子式 C6H14O6S2
分子量 246.302
闪点 234.4±24.0 °C
精确质量 246.023178
PSA 103.50000
LogP -0.52
外观性状 白色结晶。
蒸汽压 0.0±1.1 mmHg at 25°C
折射率 1.471
储存条件 Hygroscopic, Refrigerator, Under Inert Atmosphere
稳定性 Moisture Sensitive
水溶解性 Decomposes
分子结构

1、 摩尔折射率:50.94

2、 摩尔体积(cm3/mol):182.3

3、 等张比容(90.2K):476.5

4、 表面张力(dyne/cm):46.6

5、 极化率(10-24cm3):20.19

计算化学

1.疏水参数计算参考值(XlogP):无

2.氢键供体数量:0

3.氢键受体数量:6

4.可旋转化学键数量:7

5.互变异构体数量:无

6.拓扑分子极性表面积104

7.重原子数量:14

8.表面电荷:0

9.复杂度:294

10.同位素原子数量:0

11.确定原子立构中心数量:0

12.不确定原子立构中心数量:0

13.确定化学键立构中心数量:0

14.不确定化学键立构中心数量:0

15.共价键单元数量:1

更多

1.性状:白色结晶性粉末。

2.熔点(℃):119。

3.溶解性:不溶于水,但可以缓慢溶解,同时发生水解作用。在25℃丙酮中溶解度为2.4g/100ml,在乙醇中溶解度0.1g/100ml,几乎无臭。

第一部分:化学品名称
化学品中文名称: 1,4-双甲基磺氧基丁烷;二甲基磺酸1,4-丁二醇酯
化学品英文名称: 1,4-Bis(methyl sulfonoxy)butane;1,4-Butanediol dimethyl sulfonate
中文俗名或商品名:
Synonyms:
CAS No.: 55-98-1
分子式: C6H14O6S2
分子量: 246.32
第二部分:成分/组成信息
纯化学品混合物
化学品名称:1,4-双甲基磺氧基丁烷;二甲基磺酸1,4-丁二醇酯
有害物成分 含量 CAS No.
第三部分:危险性概述
危险性类别:
侵入途径: 吸入 食入 经皮吸收
健康危害: 吸入、摄入或经皮肤吸收后会引起严重中毒。可能有刺激作用。动物实验表明,长时间接触,可引起生殖系统功能紊乱。
环境危害:
燃爆危险:
第四部分:急救措施
皮肤接触: 用肥皂水及清水彻底冲洗。就医。
眼睛接触: 拉开眼睑,用流动清水冲洗15分钟。就医。
吸入: 脱离现场至空气新鲜处。就医。
食入: 误服者,饮适量温水,催吐。就医。
第五部分:消防措施
危险特性: 遇明火、高热可燃。受高热分解,放出有毒的烟气。
有害燃烧产物:
灭火方法及灭火剂: 雾状水、抗溶性泡沫、二氧化碳、干粉。
消防员的个体防护:
禁止使用的灭火剂:
闪点(℃):
自燃温度(℃):
爆炸下限[%(V/V)]:
爆炸上限[%(V/V)]:
最小点火能(mJ):
爆燃点:
爆速:
最大燃爆压力(MPa):
建规火险分级:
第六部分:泄漏应急处理
应急处理: 隔离泄漏污染区,周围设警告标志,建议应急处理人员戴自给式呼吸器,穿化学防护服。小心扫起,避免扬尘,运至废物处理场所。用水刷洗泄漏污染区,经稀释的污水放入废水系统。如大量泄漏,收集回收或无害处理后废弃。
第七部分:操作处置与储存
操作注意事项:
储存注意事项:
第八部分:接触控制/个体防护
最高容许浓度: 中 国 MAC:未制订标准前苏联 MAC:未制订标准美国TLV—TWA:未制订标准
监测方法:
工程控制: 生产过程密闭,加强通风。
呼吸系统防护: 佩戴防毒口罩。紧急事态抢救或逃生时,应该佩戴自给式呼吸器。
眼睛防护: 必要时戴化学安全防护眼镜。
身体防护: 穿相应的防护服。
手防护: 戴防化学品手套。
其他防护: 工作现场禁止吸烟、进食和饮水。工作后,淋浴更衣。保持良好的卫生习惯。避免长期反复接触。
第九部分:理化特性
外观与性状: 白色结晶。
pH:
熔点(℃): 114~118
沸点(℃):
相对密度(水=1):
相对蒸气密度(空气=1):
饱和蒸气压(kPa):
燃烧热(kJ/mol):
临界温度(℃):
临界压力(MPa):
辛醇/水分配系数的对数值:
闪点(℃):
引燃温度(℃):
爆炸上限%(V/V):
爆炸下限%(V/V):
分子式: C6H14O6S2
分子量: 246.32
蒸发速率:
粘性:
溶解性: 不溶于水,微溶于丙酮、乙醇。
主要用途: 用作有机合成反应中的强烷基化剂和慢性白血病的治疗药物。
第十部分:稳定性和反应活性
稳定性: 在常温常压下 稳定
禁配物: 强氧化剂、水、潮湿空气。
避免接触的条件: 接触潮气可分解。
聚合危害: 不能出现
分解产物: 一氧化碳、二氧化碳、氧化硫。
第十一部分:毒理学资料
急性毒性: LD50:110mg/kg(小鼠经口) LC50:
急性中毒:
慢性中毒:
亚急性和慢性毒性:
刺激性:
致敏性:
致突变性:
致畸性:
致癌性:
第十二部分:生态学资料
生态毒理毒性:
生物降解性:
非生物降解性:
生物富集或生物积累性:
第十三部分:废弃处置
废弃物性质:
废弃处置方法:
废弃注意事项:
第十四部分:运输信息
危险货物编号:
UN编号:
包装标志:
包装类别:
包装方法:
运输注意事项: 储存于阴凉、干燥、通风良好的库房。远离火种、热源。专人保管。保持容器密封。防止受潮和雨淋。应与氧化剂、食用化工原料、潮湿物品等分开存放。操作现场不得吸烟、饮水、进食。搬运时要轻装轻卸,防止包装及容器损
RETCS号:
IMDG规则页码:
第十五部分:法规信息
国内化学品安全管理法规:
国际化学品安全管理法规:
第十六部分:其他信息
参考文献: 1.周国泰,化学危险品安全技术全书,化学工业出版社,1997 2.国家环保局有毒化学品管理办公室、北京化工研究院合编,化学品毒性法规环境数据手册,中国环境科学出版社.1992 3.Canadian Centre for Occupational Health and Safety,CHEMINFO Database.1998 4.Canadian Centre for Occupational Health and Safety, RTECS Database, 1989
填表时间: 年月日
填表部门:
数据审核单位:
修改说明:
其他信息: 6
MSDS修改日期: 年月日

CHEMICAL IDENTIFICATION

RTECS NUMBER :
EK1750000
CHEMICAL NAME :
1,4-Butanediol, dimethanesulfonate
CAS REGISTRY NUMBER :
55-98-1
BEILSTEIN REFERENCE NO. :
1791786
LAST UPDATED :
199710
DATA ITEMS CITED :
139
MOLECULAR FORMULA :
C6-H14-O6-S2
MOLECULAR WEIGHT :
246.32
WISWESSER LINE NOTATION :
WS1&O4OSW1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
80 mg/kg/8Y
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - effect, not otherwise specified Vascular - regional or general arteriolar or venous dilation Gastrointestinal - changes in structure or function of salivary glands
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
8 mg/kg/2D-I
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
15 mg/kg
TOXIC EFFECTS :
Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
18 mg/kg
TOXIC EFFECTS :
Gastrointestinal - other changes Blood - changes in bone marrow (not otherwise specified) Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
22 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Gastrointestinal - hypermotility, diarrhea
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1800 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
10 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
110 mg/kg
TOXIC EFFECTS :
Gastrointestinal - hypermotility, diarrhea Skin and Appendages - hair
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
86 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Olfaction) - effect, not otherwise specified Behavioral - somnolence (general depressed activity) Gastrointestinal - hypermotility, diarrhea
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
63 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Gastrointestinal - hypermotility, diarrhea
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
46 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
8 mg/kg
TOXIC EFFECTS :
Blood - leukopenia Blood - agranulocytosis Blood - other changes
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
8 mg/kg
TOXIC EFFECTS :
Blood - leukopenia Blood - agranulocytosis Blood - other changes
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Bird - wild bird species
DOSE/DURATION :
56200 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
45 mg/kg/30D-I
TOXIC EFFECTS :
Endocrine - changes in thymus weight Blood - normocytic anemia Related to Chronic Data - changes in testicular weight
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
100 mg/kg/5D-I
TOXIC EFFECTS :
Blood - leukopenia Gastrointestinal - ulceration or bleeding from duodenum Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
5684 ug/kg/21W-C
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Blood - leukemia
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
48 mg/kg/42D-I
TOXIC EFFECTS :
Tumorigenic - neoplastic by RTECS criteria Blood - leukemia Blood - lymphoma, including Hodgkin's disease
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1200 mg/kg/8W-I
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Lungs, Thorax, or Respiration - tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
70 mg/kg/6W-I
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - aplastic anemia Blood - leukemia
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
1140 mg/kg/9Y-I
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Kidney, Ureter, Bladder - Kidney tumors Reproductive - Tumorigenic effects - other reproductive system tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
16720 ug/kg/2Y-I
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Reproductive - Tumorigenic effects - uterine tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
17 mg/kg
SEX/DURATION :
female 4-36 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - endocrine system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
17 mg/kg
SEX/DURATION :
female 4-36 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Specific Developmental Abnormalities - other developmental abnormalities Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
5400 ug/kg
SEX/DURATION :
male 90 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - breast development
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
8460 ug/kg
SEX/DURATION :
female 22 week(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
5280 ug/kg
SEX/DURATION :
female 14-26 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - gastrointestinal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
4400 ug/kg
SEX/DURATION :
female 4 week(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - menstrual cycle changes or disorders
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
10 mg/kg
SEX/DURATION :
female 13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - delayed effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
48 mg/kg
SEX/DURATION :
female 7-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
5600 ug/kg
SEX/DURATION :
female 7-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
5 mg/kg
SEX/DURATION :
female 13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
8 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
10 mg/kg
SEX/DURATION :
male 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
49 mg/kg
SEX/DURATION :
male 49 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
6 mg/kg
SEX/DURATION :
male 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
1 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - behavioral
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
10 mg/kg
SEX/DURATION :
female 2 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - other measures of fertility Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
10 mg/kg
SEX/DURATION :
female 15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Effects on Newborn - delayed effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
6 mg/kg
SEX/DURATION :
male 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
10 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
10 mg/kg
SEX/DURATION :
male 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
20 mg/kg
SEX/DURATION :
female 20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
10 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
10 mg/kg
SEX/DURATION :
female 14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
100 mg/kg
SEX/DURATION :
female 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
40 mg/kg
SEX/DURATION :
female 6-9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
240 mg/kg
SEX/DURATION :
female 6-9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
160 mg/kg
SEX/DURATION :
female 10-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
200 mg/kg
SEX/DURATION :
female 8-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
20 mg/kg
SEX/DURATION :
male 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
10 mg/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
30 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
30 mg/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - blood and lymphatic systems (including spleen and marrow)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
25 mg/kg
SEX/DURATION :
male 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
10 mg/kg
SEX/DURATION :
female 18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - delayed effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
10 mg/kg
SEX/DURATION :
male 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
32 mg/kg
SEX/DURATION :
female 7-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - hepatobiliary system Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
40 mg/kg
SEX/DURATION :
male 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
8 mg/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
4 mg/kg
SEX/DURATION :
male 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
TYPE OF TEST :
Specific locus test
TYPE OF TEST :
Sex chromosome loss and nondisjunction
TYPE OF TEST :
Sex chromosome loss and nondisjunction
TYPE OF TEST :
Sex chromosome loss and nondisjunction
TYPE OF TEST :
Heritable translocation test
TYPE OF TEST :
Mutation test systems - not otherwise specified
TYPE OF TEST :
Cytogenetic analysis
TYPE OF TEST :
Sperm Morphology
TYPE OF TEST :
Sperm Morphology
TYPE OF TEST :
Cytogenetic analysis
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
DNA damage
TYPE OF TEST :
DNA damage
TYPE OF TEST :
DNA inhibition
TYPE OF TEST :
DNA inhibition
TYPE OF TEST :
Dominant lethal test
TYPE OF TEST :
Micronucleus test
TYPE OF TEST :
Specific locus test
TYPE OF TEST :
DNA damage
TYPE OF TEST :
Unscheduled DNA synthesis
TYPE OF TEST :
Cytogenetic analysis
TYPE OF TEST :
Cytogenetic analysis
TYPE OF TEST :
Dominant lethal test
TYPE OF TEST :
Sperm Morphology
TYPE OF TEST :
Cytogenetic analysis
TYPE OF TEST :
Sister chromatid exchange

MUTATION DATA

TYPE OF TEST :
Mutation in mammalian somatic cells
TEST SYSTEM :
Rodent - hamster Ovary
DOSE/DURATION :
40 mg/L
REFERENCE :
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 43,577,1983 *** REVIEWS *** IARC Cancer Review:Animal Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 4,247,1974 IARC Cancer Review:Human Sufficient Evidence IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,137,1987 IARC Cancer Review:Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 4,247,1974 IARC Cancer Review:Group 1 IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,137,1987 TOXICOLOGY REVIEW EXHMA6 Experimental Hematology (New York). (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.1- 1973- Volume(issue)/page/year: 2,101,1974 TOXICOLOGY REVIEW JAMAAP JAMA, Journal of the American Medical Association. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1883- Volume(issue)/page/year: 172,1765,1960 TOXICOLOGY REVIEW MIMDAL Minnesota Medicine. (Minnesota Medical Assoc., 2221 University Ave., SE, Suite 400, Minneapolis, MN 55414) V.1- 1918- Volume(issue)/page/year: 57,19,1974 TOXICOLOGY REVIEW CRTXB2 CRC Critical Reviews in Toxicology. (CRC Press, Inc., 2000 Corporate Blvd., NW, Boca Raton, FL 33431) V.1- 1971- Volume(issue)/page/year: 1(1),93,1971 TOXICOLOGY REVIEW 32XPAD "Teratology," Berry, C.L., and D.E. Poswillo, eds., New York, Springer, 1975 Volume(issue)/page/year: -,49,1975 TOXICOLOGY REVIEW ARVPAX Annual Review of Pharmacology. (Palo Alto, CA) V.1-15, 1961-75. For publisher information, see ARPTDI. Volume(issue)/page/year: 5,447,1965 TOXICOLOGY REVIEW ADVPA3 Advances in Pharmacology. (New York, NY) V.1-6, 1962-68. For publisher information, see AVPCAQ. Volume(issue)/page/year: 4,263,1966 TOXICOLOGY REVIEW KMAUAI Klinische Monatsblaetter fuer Augenheilkunde. (Ferdinand Enke Verlag, POB 1304, D-7000 Stuttgart 1, Fed. Rep. Ger.) V.1- 1863- Volume(issue)/page/year: 170,818,1977 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4342 No. of Facilities: 74 (estimated) No. of Industries: 1 No. of Occupations: 3 No. of Employees: 1764 (estimated) No. of Female Employees: 892 (estimated)

符号 GHS02 GHS06 GHS08
GHS02, GHS06, GHS08
信号词 Danger
危害声明 H225-H301 + H311 + H331-H370
警示性声明 P210-P260-P280-P301 + P310-P311
危害码 (欧洲) T:Toxic
风险声明 (欧洲) R23/24/25;R36/37/38;R45;R46;R63
安全声明 (欧洲) S53-S36/37/39-S45-S28A
危险品运输编码 UN 2811 6.1/PG 1
WGK德国 3
RTECS号 EK1750000
包装等级 III
危险类别 6.1(b)
海关编码 2942000000

~86%

55-98-1结构式

55-98-1

文献:Ohta; Kohda; Kimoto; Okano; Kawazoe Chemical and Pharmaceutical Bulletin, 1988 , vol. 36, # 7 p. 2410 - 2416

~%

55-98-1结构式

55-98-1

文献:US2013/211055 A1, ; Page/Page column ;

~%

55-98-1结构式

55-98-1

文献:J. Gen. Chem. USSR (Engl. Transl.), , vol. 56, # 7 p. 1547 - 1558,1373 - 1382

~%

详细
文献:Justus Liebigs Annalen der Chemie, , vol. 631, p. 180 - 184

~%

55-98-1结构式

55-98-1

文献:Justus Liebigs Annalen der Chemie, , vol. 631, p. 180 - 184

~%

55-98-1结构式

55-98-1

文献:Justus Liebigs Annalen der Chemie, , vol. 631, p. 180 - 184

1.由甲基磺酰氯与1,4-丁二醇缩合而得。

2.制法:

于装有搅拌器、温度计、滴液漏斗的反应瓶中,加入1,4-丁二醇(2)13g(0.144mol),吡啶130g,冷却至0℃,搅拌下慢慢滴加甲基磺酰氯40g(0.35mol)。加完后继续搅拌反应2h。抽滤析出的结晶,以少量蒸馏水洗涤,干燥,得白色结晶1,4-双(甲基磺酰氯)丁烷(1)34g,mp113~116℃,收率95.8%。

海关编码 2942000000